Luteolin enhances paclitaxel-induced apoptosis in human breast cancer MDA-MB-231 cells by blocking STAT3

doi:10.1016/j.cbi.2014.02.002

中山醫學大學機構典藏 CSMUIR > 醫學院 > 生化微生物免疫研究所 > 期刊論文 > Item 310902500/10700

Please use this identifier to cite or link to this item: https://ir.csmu.edu.tw:8080/ir/handle/310902500/10700

Title:	Luteolin enhances paclitaxel-induced apoptosis in human breast cancer MDA-MB-231 cells by blocking STAT3
Authors:	Yang, Mon-Yuan Wang, Chau-Jong Chen, Nai-Fang Hoc, Wen-Hsin Lub, Fung-Jou Tseng, Tsui-Hwa
Contributors:	中山醫學大學
Keywords:	Apoptosis;Fas;Luteolin;Paclitaxel;STAT3
Date:	2013
Issue Date:	2015-05-01T04:18:18Z (UTC)
ISSN:	0009-2797
Abstract:	The potential use of low-dose chemotherapy has been appealing because lower dosages are more attainable during cancer therapy and cause less toxicity in patients. Combination therapy of paclitaxel, a promising frontline chemotherapy agent, with natural anti-tumor agents that are considerably less toxic and possess the capability of activating additional apoptotic signals may provide a rational molecular basis for novel chemotherapeutic strategies. Luteolin, a natural flavone, possesses multiple biological activities, including anti-tumor potential. In the present study, the effects of concomitant administration of luteolin and paclitaxel were investigated in human breast cancer MDA-MB-231 cells. Luteolin alone demonstrated an anti-proliferative effect. Co-administration of luteolin and paclitaxel resulted in an increase in apoptosis compared with the treatment of paclitaxel alone as evidenced by the results of a diamidino-2-phenylindole (DAPI) stain and Annexin-V-based assay. Moreover, immunoblotting analysis also showed that the co-administration of luteolin and paclitaxel activated caspase-8 and caspase-3 and increased the expression of Fas. Furthermore, the increased expression of Fas due to co-administration was shown to be due to the blocking of signal transducer and activator of transcription 3 (STAT3). Finally, combination therapy with luteolin and paclitaxel significantly reduced tumor size and tumor weight in an orthotopic tumor model of MDA-MB-231 cells in nude mice. These results suggest that the luteolin–paclitaxel combination could be a novel strategy for the treatment of breast cancer. Abbreviations DAPI, diamidino-2-phenylindole; MAPK, mitogen activated protein kinase; PARP, poly (ADP-ribose) polymerase; STAT3, signal transducer and activator of transcription 3
URI:	https://ir.csmu.edu.tw:8080/ir/handle/310902500/10700 http://dx.doi.org/10.1016/j.cbi.2014.02.002
Relation:	Chemico-Biological Interactions Volume 213, 25 April 2014, Pages 60–68
Appears in Collections:	[生化微生物免疫研究所] 期刊論文

Files in This Item:

File	Description	Size	Format
index.html	期刊論文	0Kb	HTML	381	View/Open

View Licence

Loading...